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Abstract: Acamprosate, or N-acetyl homotaurine, is an N-methyl-D-aspartate receptor 
modulator approved by the Food and Drug Administration (FDA) as a pharmacological 
treatment for alcohol dependence. The exact mechanism of action of acamprosate is still under 
investigation, but the drug appears to work by promoting a balance between the excitatory 
and inhibitory neurotransmitters, glutamate and gamma-aminobutyric acid, respectively, and 
it may help individuals with alcohol dependence by reducing withdrawal-associated distress. 
Acamprosate has low bioavailability, but also has an excellent tolerability and safety profile. In 
comparison with naltrexone and disulfiram, which are the other FDA-approved treatments for 
alcohol dependence, acamprosate is unique in that it is not metabolized by the liver and is also 
not impacted by alcohol use, so can be administered to patients with hepatitis or liver disease 
(a common comorbid condition among individuals with alcohol dependence) and to patients who 
continue drinking alcohol. Acamprosate has demonstrated its efficacy in more than 25 placebo-
controlled, double-blind trials for individuals with alcohol dependence, and has generally been 
found to be more efficacious than placebo in significantly reducing the risk of returning to any 
drinking and increasing the cumulative duration of abstinence. However, acamprosate appears 
to be no more efficacious than placebo in reducing heavy drinking days. Numerous trials have 
found that acamprosate is not significantly more efficacious than naltrexone or disulfiram, and 
the efficacy of acamprosate does not appear to be improved by combining acamprosate with other 
active medications (eg, naltrexone) or with psychosocial treatment (eg, cognitive-behavioral 
therapy). In this review, we present the data on acamprosate, including its pharmacology, 
efficacy, safety, and tolerability in the treatment of alcohol dependence.
Keywords: alcohol abuse, acamprosate, N-methyl-D-aspartate receptor, gamma- 
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Management issues in alcohol dependence
The harmful use of alcohol is a global public health problem, with nearly 2.5 million 
deaths per year attributed to alcohol worldwide. The World Health Organization1 has 
identified alcohol as the first and second leading risk factor for premature mortality 
and disability in the Americas and Europe, respectively. Alcohol dependence is one 
of the most common substance use disorders, with more than 12.5% of individuals 
in the US (roughly 38 million) meeting criteria for alcohol dependence within their 
lifetime and 3.8% (roughly 11 million) meeting criteria in the past year,2 with similar 
rates in many European countries.3
Alcohol dependence has been described as a chronic, relapsing disorder,4 with the 
majority of individuals never receiving treatment. One recent survey found that fewer 
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than 15% of individuals with a lifetime diagnosis of alcohol 
abuse or dependence have ever received treatment for alcohol 
dependence,5 and of those who do seek treatment, fewer than 
13% are provided with prescription medication for alcohol 
dependence.6 The majority of individuals with disorders 
related to alcohol use receive psychosocial intervention, such 
as cognitive-behavioral treatment, coping skills training, 
contingency management, motivation enhancement therapy, 
and mutual support groups (eg, Alcoholics Anonymous). 
Overall, most psychosocial interventions, including self-help, 
have been found to be effective in the treatment of alcohol 
dependence.7 However, the majority of patients experience 
a lapse within the first year following a psychosocial 
intervention,8,9 and there is growing evidence that combining 
psychosocial and pharmacological treatments may be an 
effective method for treating alcohol dependence.10–12
Currently, there are three medications for the treatment 
of alcohol dependence that have been approved by the 
US Food and Drug Administration (FDA), ie, disulfiram, 
  naltrexone, and acamprosate. Disulfiram blocks the 
  metabolism of acetaldehyde, which leads to severe discomfort 
when alcohol is consumed. Disulfiram has been approved for 
the treatment of alcohol dependence for over 50 years and 
has been shown to improve rates of alcohol abstinence,13 but 
numerous disadvantages of disulfiram have been identified. 
Namely, disulfiram is an aversion therapy and is only 
effective when patient compliance is high, so the continued 
use of disulfiram requires a significant level of patient 
motivation. Naltrexone is an opioid receptor antagonist that 
was approved by the FDA in 1994 as an oral medication, 
and a long-acting injectable formulation was approved in 
2006. Naltrexone appears to work by competitively binding 
to endogenous opioid receptors and reducing the pleasant 
and reinforcing effects of alcohol. Unlike disulfiram, which 
relies on aversion, naltrexone directly targets the learned 
association of experiencing euphoria following alcohol 
use. A recent meta-analysis of 50 randomized controlled 
trials of naltrexone in the treatment of 7793 patients with 
alcohol dependence found that naltrexone reduced the risk 
of heavy drinking days by 83% and decreased the number of 
drinking days by 4% in comparison with placebo.14 Numerous 
reviews of naltrexone have also found varying levels of 
responsiveness to the medication, which may be explained 
by a polymorphism in the OPRM1 gene (a µ-opioid receptor 
gene),15 although a recent prospective study of naltrexone 
in combination with cognitive-behavioral therapy failed to 
find an effect of genotype on response to treatment with 
naltrexone.16 The primary side effects of naltrexone include 
gastrointestinal problems (eg, abdominal pain, nausea), 
symptoms associated with decreased central nervous system 
arousal (eg, daytime sleepiness, fatigue), blurred vision, 
decreased libido, depression, and dizziness.14
Acamprosate, marketed in the US under the brand name 
Campral™, was approved for the treatment of alcohol 
dependence in France in 1989 and by the FDA in 2004. 
As described in more detail below, acamprosate is thought 
to promote a balance between the excitatory and inhibitory 
neurotransmitters, glutamate and gamma-aminobutyric acid 
(GABA), respectively, and may help individuals with alcohol 
dependence by modifying learned responses to alcohol cues 
and by reducing the distress associated with withdrawal. 
There is also some evidence that acamprosate may have 
neuromodulatory and neuroprotective effects.17,18 In this 
review, we present the data on acamprosate, including a brief 
overview of its pharmacology and a review of the efficacy, 
safety, and tolerability of acamprosate in the treatment of 
alcohol dependence.
Data sources
A literature review using the PubMed and EMBASE data-
bases with the search terms “acamprosate” and “alcohol 
dependence” or “alcohol use disorder” or “alcoholism” was 
conducted to find relevant articles published in English. Over 
2000 references were identified. We also reviewed completed 
and ongoing clinical trials by searching http://clinicaltrials.
gov and http://projectreporter.nih.gov. All searches were last 
updated on January 12, 2011.
Pharmacology, mode of action, and 
pharmacokinetics of acamprosate
The structure of acamprosate (N-acetyl homotaurine; 
3-(acetylamino)-1-propanesulfonic acid calcium salt) is 
similar to that of several neurotransmitters, both excitatory 
and inhibitory, and helps balance adaptations in neuronal 
firing from chronic alcohol consumption by targeting both 
N-methyl-D-aspartate (NMDA) glutamatergic and GABA 
receptor activity.19
Due to its structural similarity to GABA and taurine, the 
potential for acamprosate to act on inhibitory receptors was 
an early focus,20 but more recent research indicates little 
influence of acamprosate on GABAA or glycine receptors, 
either independently or in the presence of ethanol,21 and cur-
rent efforts have shifted toward examining the mechanism 
of action of acamprosate at NMDA receptors.
Acamprosate appears to act as a partial coagonist of 
NMDA receptors, depending on its concentration and the 
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activity of the NMDA receptor, where at low concentrations 
acamprosate increases low receptor activity and at high 
concentrations inhibits highly activated NMDA receptors.22 
The precise mode of action is not fully understood, but recent 
studies suggest that acamprosate is an NMDA receptor 
modulator17 rather than a direct antagonist, potentially 
working via a spermidine-sensitive binding site.22 Upon 
further examination, acamprosate may be responsible 
for regulating NMDA subunit synthesis, indicating an 
important role in amending the changes caused by chronic 
alcohol consumption rather than acutely antagonizing 
NMDA-mediated glutamatergic neurotransmission.23 Thus, 
acamprosate helps balance disrupted neurotransmission, 
mainly by decreasing the overexcitation caused by alcohol 
dependence. Acamprosate is most likely absorbed via a 
paracellular route24 and overall bioavailability is relatively low 
(11%).25 Maximum plasma concentrations were observed to 
range from 4.3–15.3 hours after acute oral administration of 
varying formulas but dropped to 3.5–9.5 hours when steady 
state was reached.25 A steady state has consistently been 
observed between 5 and 7 days.25,26 Limited absorption after 
oral administration results in a majority of the drug being 
excreted in fecal matter,25 so amounts excreted in urine may 
be directly correlated with its bioavailability.24 Acamprosate is 
not processed significantly in the liver and does not appear to 
have any metabolites, leaving little threat of interactions with 
other drugs, including naltrexone,27 disulfiram, diazepam, 
or alcohol, but taking food with acamprosate does appear to 
limit its absorption even further.25
Efficacy in alcohol dependence
The efficacy of acamprosate in the treatment of alcohol 
dependence was recently evaluated in a comprehensive 
Cochrane review that included 24 randomized controlled 
trials of 6894 patients with the disorder. The 24 randomized 
controlled trials included in the Cochrane review all used a 
double-blind design to compare the effects of acamprosate 
(alone or in combination) with placebo or an active treatment 
control group. The primary outcomes of the review included 
returning to any drinking and cumulative duration of 
abstinence (ie, the sum of days a patient remained abstinent 
during the study). The secondary outcomes included return 
to heavy drinking (defined in most studies as five or more 
standard drinks per occasion), liver enzyme levels (gamma-
glutamyl transpeptidase), and side effects. A meta-analysis 
of the 24 trials indicated a statistically significant effect of 
acamprosate in comparison with placebo on both of the 
primary outcomes. Receiving acamprosate significantly 
reduced the risk of returning to any drinking by 86% 
(95% confidence interval [CI]: 81%–91%) and increased the 
cumulative duration of abstinence by 11% (95% CI: 5%–16%) 
compared with placebo during treatment. A statistically 
significant difference between groups was also observed 
3–12 months after treatment was discontinued. Individuals 
who received acamprosate had a 9% lower risk of returning to 
any drinking and a 9% higher continuous abstinence duration 
in comparison with placebo after discontinuing treatment. 
The Cochrane review did not find significant differences 
between the acamprosate and placebo groups on return to 
heavy drinking or on gamma-glutamyl transpeptidase, and 
the review also did not find significant differences between 
acamprosate and naltrexone on the primary outcomes or 
return to heavy drinking. There was a significant difference 
between acamprosate and naltrexone on gamma-glutamyl 
transpeptidase. Likewise, the combination of acamprosate 
and naltrexone did not lead to significant differences in 
primary or secondary outcomes, as compared with placebo 
or as compared with acamprosate monotherapy.
The Cochrane review and other reviews of acamprosate18,28,29 
have generally omitted open-label and single-blind studies 
because they often lack the rigorous standards of double-
blind, randomized trials and can be lower in internal   validity. 
It is also the case that double-blind, placebo-controlled, 
randomized trials are sometimes lower in external validity. 
For this reason, we believe that it is important to consider 
the findings from less methodologically rigorous evaluations 
of acamprosate in addition to the review of the double-blind, 
placebo-controlled trials described above. The Cochrane 
review excluded 24 trials of acamprosate in the treatment of 
alcohol dependence for a variety of reasons, including open-
label or single-blind design, lack of placebo or active control 
groups, treatment duration below 30 days, or follow-up 
duration less than 8 weeks, and nonavailability of data. Of 
these 24 trials, we provide an overview of the findings from 
nine open-label and single-blind studies in Table 1.
As seen in Table 1, acamprosate was less effective than 
naltrexone30,31 and disulfiram,31,32 was more effective than 
  placebo or standard care,33,34 and was not significantly dif-
ferent from oxcarbazepine.35 Overall, the average   number 
of days until the first drinking day among those who 
received acamprosate ranged from 6635 to 81.5 days,36 while 
the   average days until the first drinking day among the 
  comparison groups ranged from 96 days for oxcarbazepine35 
to 123 days for disulfiram.32 The average number of days to a 
heavy drinking day or severe lapse among those who received 
acamprosate ranged from 17.6 days31 to 77 days,35 while 
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the average days until the first heavy drinking day or severe 
lapse among the comparison groups ranged from 22 days for 
naltrexone31 to 97 days for oxcarbazepine.35
Additional randomized controlled trials have been 
  published since the Cochrane review was completed, with 
the latest studies included in the Cochrane review published 
in 2006. To address this gap we will briefly summarize each 
of the randomized trials that have been published since 
2006. Most recently, acamprosate was combined with either 
integrative behavioral therapy or supportive counseling, and 
was compared with integrative behavioral therapy and placebo 
in a randomized, double-blind multisite study.12 A total of 
371 individuals were randomized to one of the three treatments 
(acamprosate + behavioral therapy, acamprosate + supportive 
counseling, or placebo + behavioral therapy) administered 
for 6 months, and patients were followed for 3 and 6 months 
after discontinuation of treatment. Importantly, individuals 
were dropped from the study if they used any alcohol 
during treatment (40.3% of 201 dropouts) or missed three 
consecutive sessions (35.3% of 201 dropouts). At the end of 
the 6-month treatment and up to 6 months following treatment, 
there were no significant differences in success (nonlapsed) 
rates between the three groups. The best outcomes were 
observed in the acamprosate + behavioral therapy condition 
(47.6% success rate at end of treatment and 35% success 
rate at 6-month follow-up) and the placebo + behavioral 
therapy condition (48% success rate at end of treatment 
and 32% success rate at 6-month follow-up), as compared 
with the acamprosate + supportive counseling condition 
(37.7% success rate at end of treatment and 32% success rate 
at 6-month follow-up). Other drinking outcomes (eg, rates of 
moderate, nonheavy drinking) were not reported.
Compliance and patient response
Importantly, compliance with medication plays an important 
role in the efficacy of acamprosate. One recent meta-analysis 
of individual patient data (n = 2305) from 11 randomized 
controlled trials comparing acamprosate with placebo 
found that those individuals who took at least 80% of their 
prescribed medication during the early phases of treatment 
were five times more likely to complete treatment and had 
a significantly higher percentage of abstinence days than 
those individuals who were not compliant.37 The authors also 
found a significant compliance by treatment interaction in 
the prediction of abstinence days. Individuals who complied 
with acamprosate had 8.4% more improvement in percent-
age of abstinent days than individuals who complied with 
placebo. Those individuals who complied with acamprosate 
50% of the time had only a 4.2% improvement in   percentage 
of abstinent days as compared with those individuals who 
complied with placebo. These findings are noteworthy given 
the three times daily dosing and unpleasant side effects 
of acamprosate (eg, nausea, diarrhea), which may cause 
  disruptions in compliance. In the largest randomized clinical 
trial of acamprosate conducted to date,10 mean adherence 
to acamprosate monotherapy was only 69.7% and mean 
adherence to acamprosate combined with naltrexone was 
only 64.9%.
Genetic factors may also play a role in the patient response 
to acamprosate. Kiefer et al38 found that genetic variations in 
a gene for GATA-binding protein (GATA4) was significantly 
associated with relapse risk during a 90-day medical   treatment 
period and that the risk was primarily driven by those 
patients who were treated with acamprosate as compared 
with those treated with naltrexone or placebo. Similarly, in 
a novel study of genetic risk factors interacting with either 
naltrexone or acamprosate in the prediction of alcohol 
cue reactivity, Ooteman et al39 found interactions between 
medication condition and polymorphisms of the GABRA6 
and DRD2 genotypes in prediction of cue-induced craving. 
The efficacy of acamprosate on cue-induced craving depended 
on the frequency of the C allele of the GABRA6 gene. For 
the DRD2 gene, acamprosate outperformed naltrexone 
among A1 allele carriers and naltrexone outperformed 
acamprosate among A2 allele carriers. The genetic findings 
from these two studies need to be replicated prior to making 
any definite conclusion, but the results are promising for 
future pharmacogenetic research on the efficacy of matching 
acamprosate to profiles of genetic risk.
Safety and tolerability
Acamprosate has been described as having an “excellent 
safety profile”.40 Perhaps most important for the treatment 
of alcohol dependence, acamprosate is not metabolized 
by liver enzymes and alcohol has no effect on the 
pharmacokinetics of acamprosate. Acamprosate is excreted 
through the kidneys and is contraindicated for individuals 
with severe renal impairment. A systematic review of the 
published literature from 1990 to 2002 found that patients 
who received acamprosate generally reported few adverse 
effects and also reported fewer adverse effects than those 
patients who received naltrexone.41 In the Cochrane review, 
only diarrhea was reported significantly more often for 
acamprosate than for placebo, but the dropout rate due 
to side effects was 35% higher in the acamprosate group 
than in the placebo group. Other side effects reported 
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in the studies reviewed by the Cochrane group included 
abdominal pain (three studies), constipation (three   studies), 
nausea (five studies), vomiting (three studies), other 
gastrointestinal symptoms (eight   studies), pruritus (four 
studies), and a variety of side effects were reported in one 
or two of the studies reviewed.
Rosenthal et al42 conducted an analysis of acamprosate 
safety and tolerability data pooled from 13 large randomized, 
double-blind, placebo-controlled trials of acamprosate for 
alcohol dependence. Their analysis included 2272 patients 
who received acamprosate doses of 1998–2000 mg/day 
(n = 1749), 1132 mg/day (n = 440), and 3000 mg/day (n = 83) 
for an average of 12.7–34.7 weeks. The overall incidence of 
adverse events pooled across the acamprosate groups was 
61% (as compared with 56% in the pooled placebo groups). 
Dropout due to adverse events was not significantly different 
between the pooled acamprosate (7% in shorter trials, 8% 
in longer trials) and pooled placebo groups (6% in shorter 
trials, 7% in longer trials). Consistent with the data from the 
Cochrane review, diarrhea was the most common adverse 
event and was reported significantly more often (P , 0.01) 
by acamprosate patients (16%) than by placebo patients 
(10%). The patients reported only mild or moderate diar-
rhea, and the incidence of diarrhea decreased after 4 weeks. 
Serious adverse events (defined as any event that was fatal, 
life  threatening, or resulted in prolonged hospitalization, 
disability/incapacity, birth defect, cancer, or overdose) were 
slightly more common among the acamprosate groups 
(7% in shorter trials, 14% in longer trials), as compared 
with the placebo groups (5% in shorter trials, 11% in lon-
ger trials), although no significant differences in serious 
adverse events were found in a between-group analysis of 
the pooled acamprosate versus pooled placebo data.
Overall, numerous narrative and meta-analytic reviews 
have concluded that acamprosate is safe and well tolerated 
by patients with alcohol dependence.51,52,40–43 Notably, of the 
three FDA-approved medications for alcohol dependence, 
acamprosate is the only medication that is not associated with 
liver toxicity (naltrexone is contraindicated in patients with 
hepatitis or liver failure) and is also not impacted by alcohol 
use (disulfiram and alcohol consumption results in signifi-
cant physical symptoms). In a risk-benefit analysis compar-
ing double-blind, placebo-controlled trials of acamprosate 
and/or naltrexone in the treatment of alcohol dependence, 
Mason44 concluded that acamprosate is more reliably effec-
tive and is often better tolerated, which is consistent with later 
reviews that found acamprosate to be associated with fewer 
adverse events in comparison with naltrexone.41
Acamprosate in clinical practice
Based on the available evidence and reviews of acamprosate 
conducted to date, we conclude that acamprosate is an effica-
cious treatment for alcohol dependence and is well tolerated 
by patients. Acamprosate also has no abuse potential and 
does not have significant drug interactions with many of 
the medications that are commonly used to treat alcohol 
dependence and other psychiatric disorders (including nal-
trexone, antidepressants, anxiolytics, and hypnotics).42 Few 
serious adverse events associated with acamprosate have 
been reported across studies and fewer than 8% of patients 
have dropped out of treatment because of the side effects of 
acamprosate,42 which is lower than the 10% rate of dropout 
due to the side effects of naltrexone.41
The question of whether acamprosate is a cost-effective 
treatment was recently evaluated in a systematic review of 
economic evaluations of pharmacotherapy in the treatment 
of alcohol dependence. Although the number of studies 
identified for the review was limited to only seven trials, 
the results clearly indicated a net benefit of acamprosate, 
naltrexone, or their combination. Cost-effectiveness of the 
COMBINE (Combined Pharmacotherapies and Behavioral 
Interventions for Alcohol Dependence) study, the largest 
randomized controlled trial of acamprosate conducted to 
date,45 found that naltrexone or the combination of naltrexone 
with acamprosate produced the greatest cost savings with 
respect to their effectiveness in increasing percent days of 
abstinence and increasing the proportion of patients who 
avoided heavy drinking and were determined to have good 
clinical outcomes.46 A second analysis of the COMBINE 
study evaluated the cost-effectiveness of each treatment 
condition from the patient’s perspective by calculating total 
costs, effectiveness, and the patient time costs (eg, time 
spent traveling to and from treatment).47 Again, the results 
indicated that placebo, naltrexone, or the combination of 
naltrexone and acamprosate, were the most cost-effective 
treatments. Finally, there is evidence that acamprosate may 
be associated with reduced lifetime costs due to greater life 
expectancy that follows the greater abstinence rates achieved 
while taking acamprosate.48,49
Given that acamprosate has been shown to be efficacious, 
but no more efficacious than alternative medications for 
alcohol dependence,50 an important next step is to examine 
whether certain individuals are more or less likely to ben-
efit from acamprosate than from other medications.17,51,52 
  Pharmacogenomics has started to reveal that the efficacy of 
acamprosate may be enhanced by certain genotypes,39 although 
these findings will need to be replicated. Some   studies have 
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found that individuals with a goal of total abstinence and 
those patients who are highly motivated may be more likely 
to benefit from acamprosate than from naltrexone or pla-
cebo,37,53 while another study found that acamprosate worked 
better for individuals who were very frequent drinkers prior 
to starting treatment and less well for those   individuals who 
had more days of abstinence prior to treatment.54 Another 
intriguing finding is that acamprosate does not appear to 
confer additional benefits when prescribed in combination 
with behavioral interventions,12, although there may be some 
benefit to providing a motivational intervention prior to start-
ing treatment with acamprosate.53
In addition to understanding who will benefit from 
acamprosate, more research needs to be done on the neuro-
biological and behavioral mechanisms of change. Recent data 
suggest that acamprosate may be effective by normalizing 
dysregulated NMDA-mediated glutamatergic neurotrans-
mission, which may serve to reduce alcohol withdrawal-
related distress and craving.55,56 Another study found that 
acamprosate may be partially effective by reducing the 
sleep disturbances that are often found among individuals 
in alcohol withdrawal.31 Preclinical studies have found that 
acamprosate has effects on alcohol self-administration and 
cue-induced reinstatement of alcohol-seeking,57–59 so it has 
been proposed that acamprosate may work by reducing 
withdrawal-related and cue-induced craving.18 A recent 
study in alcohol-dependent patients found acamprosate-
induced attenuation of craving in response to a priming dose 
of alcohol and this effect was correlated with the plasma 
concentration of acamprosate.60 Furthermore, individuals 
who received acamprosate experienced less of an elevation 
in cortisol levels following alcohol administration, which 
suggests that acamprosate may play a role in stabilizing 
hypothalamic-pituitary-adrenal axis functioning.60
In summary, acamprosate has been shown to be an effec-
tive medication in the treatment of alcohol dependence. 
However, the effects of acamprosate are only moderate in 
comparison with placebo and acamprosate has not been 
found to be consistently superior to naltrexone or disulfiram. 
Furthermore, there have not been any prospective studies 
evaluating the long-term (longer than one year) effectiveness 
of acamprosate in preventing lapse following discontinua-
tion of the medication and retrospective studies have found 
the long-term effectiveness of acamprosate to be worse than 
that of disulfiram in a naturalistic clinical setting.61 Finally, it 
is imperative that more research be devoted to studying the 
mechanisms of efficacy for acamprosate and to determine 
whether certain patients are more or less likely to respond to 
this agent, as compared with other FDA-approved medications 
for alcohol dependence.
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